vs
花花公子（PLBY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
花花公子的季度营收约是REGENXBIO Inc.的1.2倍（$34.9M vs $30.3M），花花公子净利率更高（10.3% vs -221.3%，领先231.6%），REGENXBIO Inc.同比增速更快（43.0% vs 4.2%），花花公子自由现金流更多（$1.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 11.0%）
花花公子集团（Playboy, Inc.）起源于1953年由休·海夫纳联合合伙人在美国芝加哥创立，初始部分资金来自海夫纳母亲提供的1000美元贷款，是美国知名生活方式与娱乐内容品牌，旗下核心《花花公子》杂志同时发行电子版与纸质版。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PLBY vs RGNX — 直观对比
营收规模更大
PLBY
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出38.8%
4.2%
净利率更高
PLBY
高出231.6%
-221.3%
自由现金流更多
PLBY
多$53.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
11.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.9M | $30.3M |
| 净利润 | $3.6M | $-67.1M |
| 毛利率 | 73.3% | — |
| 营业利润率 | 7.9% | -190.0% |
| 净利率 | 10.3% | -221.3% |
| 营收同比 | 4.2% | 43.0% |
| 净利润同比 | 128.6% | -31.2% |
| 每股收益（稀释后） | $0.05 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLBYRGNX
| Q4 25 | $34.9M | $30.3M | ||
| Q3 25 | $29.0M | $29.7M | ||
| Q2 25 | $28.1M | $21.4M | ||
| Q1 25 | $28.9M | $89.0M | ||
| Q4 24 | $33.5M | $21.2M | ||
| Q3 24 | $29.4M | $24.2M | ||
| Q2 24 | $24.9M | $22.3M | ||
| Q1 24 | $28.3M | $15.6M |
净利润PLBYRGNX
| Q4 25 | $3.6M | $-67.1M | ||
| Q3 25 | $460.0K | $-61.9M | ||
| Q2 25 | $-7.7M | $-70.9M | ||
| Q1 25 | $-9.0M | $6.1M | ||
| Q4 24 | $-12.5M | $-51.2M | ||
| Q3 24 | $-33.8M | $-59.6M | ||
| Q2 24 | $-16.7M | $-53.0M | ||
| Q1 24 | $-16.4M | $-63.3M |
毛利率PLBYRGNX
| Q4 25 | 73.3% | — | ||
| Q3 25 | 76.0% | — | ||
| Q2 25 | 65.4% | — | ||
| Q1 25 | 68.6% | — | ||
| Q4 24 | 70.8% | 70.2% | ||
| Q3 24 | 61.0% | 48.8% | ||
| Q2 24 | 67.8% | 52.5% | ||
| Q1 24 | 55.8% | 72.6% |
营业利润率PLBYRGNX
| Q4 25 | 7.9% | -190.0% | ||
| Q3 25 | 4.7% | -176.3% | ||
| Q2 25 | -20.9% | -296.3% | ||
| Q1 25 | -21.7% | 13.6% | ||
| Q4 24 | -13.3% | -242.1% | ||
| Q3 24 | -96.0% | -256.6% | ||
| Q2 24 | -37.0% | -251.3% | ||
| Q1 24 | -31.5% | -408.8% |
净利率PLBYRGNX
| Q4 25 | 10.3% | -221.3% | ||
| Q3 25 | 1.6% | -208.3% | ||
| Q2 25 | -27.3% | -331.8% | ||
| Q1 25 | -31.3% | 6.8% | ||
| Q4 24 | -37.4% | -241.3% | ||
| Q3 24 | -114.7% | -246.3% | ||
| Q2 24 | -66.9% | -237.7% | ||
| Q1 24 | -58.1% | -405.4% |
每股收益（稀释后）PLBYRGNX
| Q4 25 | $0.05 | $-1.30 | ||
| Q3 25 | $0.00 | $-1.20 | ||
| Q2 25 | $-0.08 | $-1.38 | ||
| Q1 25 | $-0.10 | $0.12 | ||
| Q4 24 | $-0.13 | $-0.99 | ||
| Q3 24 | $-0.45 | $-1.17 | ||
| Q2 24 | $-0.23 | $-1.05 | ||
| Q1 24 | $-0.23 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.8M | $230.1M |
| 总债务越低越好 | $174.2M | — |
| 股东权益账面价值 | $18.4M | $102.7M |
| 总资产 | $292.4M | $453.0M |
| 负债/权益比越低杠杆越低 | 9.48× | — |
8季度趋势，按日历期对齐
现金及短期投资PLBYRGNX
| Q4 25 | $37.8M | $230.1M | ||
| Q3 25 | $27.5M | $274.2M | ||
| Q2 25 | $19.6M | $323.3M | ||
| Q1 25 | $23.7M | $267.9M | ||
| Q4 24 | $30.9M | $234.7M | ||
| Q3 24 | $9.5M | $255.5M | ||
| Q2 24 | $16.9M | $290.4M | ||
| Q1 24 | $19.0M | $338.7M |
总债务PLBYRGNX
| Q4 25 | $174.2M | — | ||
| Q3 25 | $176.8M | — | ||
| Q2 25 | $177.5M | — | ||
| Q1 25 | $176.3M | — | ||
| Q4 24 | $176.6M | — | ||
| Q3 24 | $200.0M | — | ||
| Q2 24 | $196.3M | — | ||
| Q1 24 | $193.4M | — |
股东权益PLBYRGNX
| Q4 25 | $18.4M | $102.7M | ||
| Q3 25 | $3.8M | $161.5M | ||
| Q2 25 | $-17.5M | $213.7M | ||
| Q1 25 | $-11.4M | $274.2M | ||
| Q4 24 | $-7.7M | $259.7M | ||
| Q3 24 | $-15.7M | $301.4M | ||
| Q2 24 | $15.7M | $348.3M | ||
| Q1 24 | $29.5M | $390.7M |
总资产PLBYRGNX
| Q4 25 | $292.4M | $453.0M | ||
| Q3 25 | $278.3M | $525.2M | ||
| Q2 25 | $264.1M | $581.0M | ||
| Q1 25 | $270.6M | $490.9M | ||
| Q4 24 | $284.7M | $466.0M | ||
| Q3 24 | $271.5M | $519.1M | ||
| Q2 24 | $301.8M | $569.4M | ||
| Q1 24 | $309.1M | $629.2M |
负债/权益比PLBYRGNX
| Q4 25 | 9.48× | — | ||
| Q3 25 | 46.86× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 12.51× | — | ||
| Q1 24 | 6.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $1.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 3.2% | -174.0% |
| 资本支出强度资本支出/营收 | 0.8% | 1.7% |
| 现金转化率经营现金流/净利润 | 0.39× | — |
| 过去12个月自由现金流最近4个季度 | $-1.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PLBYRGNX
| Q4 25 | $1.4M | $-52.3M | ||
| Q3 25 | $10.1M | $-56.0M | ||
| Q2 25 | $-3.9M | $-49.3M | ||
| Q1 25 | $-7.6M | $33.6M | ||
| Q4 24 | $161.0K | $-31.6M | ||
| Q3 24 | $-6.5M | $-40.5M | ||
| Q2 24 | $-3.0M | $-45.5M | ||
| Q1 24 | $-9.8M | $-55.5M |
自由现金流PLBYRGNX
| Q4 25 | $1.1M | $-52.8M | ||
| Q3 25 | $9.8M | $-56.5M | ||
| Q2 25 | $-4.3M | $-49.7M | ||
| Q1 25 | $-7.7M | $32.6M | ||
| Q4 24 | $-401.0K | $-32.7M | ||
| Q3 24 | $-7.0M | $-40.9M | ||
| Q2 24 | $-3.7M | $-46.0M | ||
| Q1 24 | $-10.3M | $-56.0M |
自由现金流率PLBYRGNX
| Q4 25 | 3.2% | -174.0% | ||
| Q3 25 | 33.8% | -189.9% | ||
| Q2 25 | -15.2% | -232.8% | ||
| Q1 25 | -26.5% | 36.6% | ||
| Q4 24 | -1.2% | -154.2% | ||
| Q3 24 | -23.7% | -168.9% | ||
| Q2 24 | -14.8% | -206.2% | ||
| Q1 24 | -36.5% | -358.5% |
资本支出强度PLBYRGNX
| Q4 25 | 0.8% | 1.7% | ||
| Q3 25 | 1.1% | 1.7% | ||
| Q2 25 | 1.4% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 1.7% | 5.1% | ||
| Q3 24 | 1.5% | 1.3% | ||
| Q2 24 | 2.6% | 2.1% | ||
| Q1 24 | 2.1% | 3.6% |
现金转化率PLBYRGNX
| Q4 25 | 0.39× | — | ||
| Q3 25 | 22.02× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLBY
| Transferred At Point In Time | $22.2M | 64% |
| Trademark Licensing | $6.5M | 19% |
| Related Party | $5.0M | 14% |
| Other | $1.1M | 3% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
